124 related articles for article (PubMed ID: 37806336)
1. Antagonism of androgen receptor signaling by aloe-emodin.
Zhao J; Sun Y; Ren L; Huang S; Zhang J
Food Chem Toxicol; 2023 Nov; 181():114092. PubMed ID: 37806336
[TBL] [Abstract][Full Text] [Related]
2. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
Cha TL; Qiu L; Chen CT; Wen Y; Hung MC
Cancer Res; 2005 Mar; 65(6):2287-95. PubMed ID: 15781642
[TBL] [Abstract][Full Text] [Related]
3. Aloe-Emodin Isolated from
He MT; Nguyen QN; Cho EJ; Kim SH; Park S; Park JY; Lee S; Kang KS
J Diet Suppl; 2024; 21(3):389-407. PubMed ID: 38062982
[TBL] [Abstract][Full Text] [Related]
4. Emodin induces apoptosis in human prostate cancer cell LNCaP.
Yu CX; Zhang XQ; Kang LD; Zhang PJ; Chen WW; Liu WW; Liu QW; Zhang JY
Asian J Androl; 2008 Jul; 10(4):625-34. PubMed ID: 18478162
[TBL] [Abstract][Full Text] [Related]
5. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
[TBL] [Abstract][Full Text] [Related]
7. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
[TBL] [Abstract][Full Text] [Related]
8. Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2.
Liu K; Park C; Li S; Lee KW; Liu H; He L; Soung NK; Ahn JS; Bode AM; Dong Z; Kim BY; Dong Z
Carcinogenesis; 2012 Jul; 33(7):1406-11. PubMed ID: 22532249
[TBL] [Abstract][Full Text] [Related]
9. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
10. Exploration of effects of emodin in selected cancer cell lines: enhanced growth inhibition by ascorbic acid and regulation of LRP1 and AR under hypoxia-like conditions.
Masaldan S; Iyer VV
J Appl Toxicol; 2014 Jan; 34(1):95-104. PubMed ID: 23212659
[TBL] [Abstract][Full Text] [Related]
11. A synthetic decursin analog with increased in vivo stability suppresses androgen receptor signaling in vitro and in vivo.
Zhang Y; Shaik AA; Xing C; Chai Y; Li L; Zhang J; Zhang W; Kim SH; Lü J; Jiang C
Invest New Drugs; 2012 Oct; 30(5):1820-9. PubMed ID: 21870073
[TBL] [Abstract][Full Text] [Related]
12. White button mushroom (Agaricus bisporus) disrupts androgen receptor signaling in human prostate cancer cells and patient-derived xenograft.
Wang X; Ha D; Mori H; Chen S
J Nutr Biochem; 2021 Mar; 89():108580. PubMed ID: 33388344
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
14. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
15. Discovery of thiohydantoin based antagonists of androgen receptor with efficient degradation for the treatment of prostate cancer.
Chang X; Zhang D; Qu F; Xie Y; Chen T; Zhang Y; Du Q; Bian J; Li Z; Wang J; Xu X
Eur J Med Chem; 2023 Sep; 257():115490. PubMed ID: 37209451
[TBL] [Abstract][Full Text] [Related]
16. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.
Darshan MS; Loftus MS; Thadani-Mulero M; Levy BP; Escuin D; Zhou XK; Gjyrezi A; Chanel-Vos C; Shen R; Tagawa ST; Bander NH; Nanus DM; Giannakakou P
Cancer Res; 2011 Sep; 71(18):6019-29. PubMed ID: 21799031
[TBL] [Abstract][Full Text] [Related]
17. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.
Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A
Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674
[TBL] [Abstract][Full Text] [Related]
18. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
Yan J; Xie B; Capodice JL; Katz AE
Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
[TBL] [Abstract][Full Text] [Related]
19. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells.
Nakka M; Agoulnik IU; Weigel NL
Int J Biochem Cell Biol; 2013 Apr; 45(4):763-72. PubMed ID: 23270728
[TBL] [Abstract][Full Text] [Related]
20. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
